{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:27:08Z","timestamp":1793647628178,"version":"4.5.1"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Immune checkpoint inhibitors (ICIs) have improved outcomes in advanced lung cancer. \u03b2-adrenergic signaling may promote tumor initiation and progression, and \u03b2-blockers (BBs) have emerged as anti-tumor sensitizing agents. This study evaluates the impact of BBs use during ICIs treatment in advanced lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This multicenter retrospective real-world study included 462 patients treated with ICIs from June 2019 to December 2024. Patients were divided into BBs and No BBs groups. Primary endpoints were overall survival (OS) and progression-free survival (PFS); efficacy evaluation and objective response rate (ORR) were secondary. Propensity score matching (PSM) balances baseline characteristics. Kaplan\u2013Meier method, Cox, and logistic regression models were used for survival and multivariate analyses. Subgroup analyses assessed clinical factors. A P value &amp;lt; 0.05 is considered statistically significant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After PSM, 318 patients were included (88 BBs, 230 No BBs). BBs use was associated with longer median PFS (mPFS) (15.8 vs. 11.8 months; HR = 0.67, 95% CI: 0.49\u20130.92, P = 0.038) and higher ORR (51.1% vs. 35.2%, P = 0.014), but not improved median OS (mOS) (29.0 vs. 31.5 months; HR = 1.38, 95% CI: 0.93\u20132.03, P = 0.108). BBs use independently predicted improved ORR (OR = 0.45, 95% CI: 0.26\u20130.78, P = 0.004) and longer PFS (HR = 0.67, 95% CI: 0.49\u20130.92, P = 0.014). In patients with cardiovascular comorbidities (CVD), BBs use was linked to longer mPFS (15.8 vs. 10.9 months, P = 0.0066) and higher ORR(51.1% vs 27.0%, P&amp;lt;0.001), with no mOS difference (P = 0.82). Among non-small cell lung cancer (NSCLC) patients, mPFS (17.5 vs. 12.3 months, P = 0.04) and ORR (56.0% vs 35.9%, P = 0.004) were also improved in the BBs group, whereas OS did not differ significantly (P = 0.3).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In stage-advanced lung cancer, BBs combined with ICIs were associated with improved ORR and prolonged PFS, but did not significantly improve OS. PFS and ORR benefits were also observed in patients with CVD or NSCLC. Further prospective studies are needed to validate these findings and clarify whether BBs directly contribute to ICIs\u2019 efficacy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1693249","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:37:56Z","timestamp":1761025076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of \u03b2-blockers on outcomes of immune checkpoint inhibitors therapy in advanced lung cancer: a multicenter real-world study"],"prefix":"10.3389","volume":"16","author":[{"given":"Lingdan","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jilan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjin","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-2024-2198","article-title":"Correlation of inflammatory markers with progression-free survival in advanced lung cancer patients treated with immune checkpoint inhibitors in combination with chemotherapy: a real-world study","volume":"17","author":"Li","year":"2025","journal-title":"J Thorac Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nature21508","article-title":"Immunology: The chronicles of T-cell exhaustion","volume":"543","author":"Amezquita","year":"2017","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1520766","article-title":"Single-cell RNA sequencing reveals adrb1 as a sympathetic nerve-regulated immune checkpoint driving T cell exhaustion and impacting immunotherapy in esophageal squamous cell carcinoma","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06110-8","article-title":"Tumour immune rejection triggered by activation of \u03b12-adrenergic receptors","volume":"618","author":"Zhu","year":"2023","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06568-6","article-title":"The \u03b2(1)-adrenergic receptor links sympathetic nerves to T\u2009cell exhaustion","volume":"622","author":"Globig","year":"2023","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"100066","DOI":"10.1016\/j.esmoop.2021.100066","article-title":"Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis","volume":"6","author":"Caparica","year":"2021","journal-title":"ESMO Open"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e000230","DOI":"10.1136\/openhrt-2014-000230","article-title":"\u03b2-Blockers in hypertension, diabetes, heart failure and acute myocardial infarction: a review of the literature","volume":"2","author":"DiNicolantonio","year":"2015","journal-title":"Open Heart"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e52194","DOI":"10.7759\/cureus.52194","article-title":"Beta-adrenergic blockade in advanced non-small cell lung cancer patients receiving immunotherapy: A multicentric study","volume":"16","author":"Duarte Mendes","year":"2024","journal-title":"Cureus"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04159-y","article-title":"Effect of concurrent beta-blocker use in patients receiving immune checkpoint inhibitors for advanced solid tumors","volume":"149","author":"Mellgard","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/cancers17081357","article-title":"The impact of beta blockers on survival in cancer patients: A systematic review and meta-analysis","volume":"17","author":"Sharma","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1128569","article-title":"Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors","volume":"13","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"104474","DOI":"10.1016\/j.breast.2025.104474","article-title":"Beta blocker use and breast cancer survival by subtypes: A population-based cohort study","volume":"81","author":"Scott","year":"2025","journal-title":"N\/A"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds616","article-title":"Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy","volume":"24","author":"Wang","year":"2013","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"10702","DOI":"10.1038\/s41598-025-93205-z","article-title":"Beta-adrenergic receptor blockers improve survival in patients with advanced non-small cell lung cancer combined with hypertension undergoing radiotherapy","volume":"15","author":"Liang","year":"2025","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3390\/cancers15041277","article-title":"Beta blockers with statins may decrease all-cause mortality in patients with cardiovascular diseases and locally advanced unresectable non-small-cell lung cancer after chemoradiotherapy","volume":"15","author":"Zaborowska-Szmit","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2020.07.016","article-title":"The impact of beta blockers on survival outcomes in patients with non-small-cell lung cancer treated with immune checkpoint inhibitors","volume":"22","author":"Oh","year":"2021","journal-title":"Clin Lung Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"109383","DOI":"10.1016\/j.intimp.2022.109383","article-title":"Novel evidence for the prognostic impact of \u03b2-blockers in solid cancer patients receiving immune checkpoint inhibitors","volume":"113","author":"Yan","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"131642","DOI":"10.1016\/j.ijcard.2023.131642","article-title":"The prognostic value of beta-1 blockers in patients with non-small-cell lung carcinoma treated with pembrolizumab","volume":"397","author":"Leshem","year":"2024","journal-title":"Int J Cardiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.21972","article-title":"World medical association declaration of helsinki: ethical principles for medical research involving human participants","volume":"333","year":"2025","journal-title":"JAMA"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0659","article-title":"The eighth edition of TNM staging of lung cancer: reference chart and diagrams","volume":"23","author":"Lababede","year":"2018","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3332\/ecancer.2019.913","article-title":"How do clinicians rate patient\u2019s performance status using the ECOG performance scale? A mixed-methods exploration of variability in decision-making in oncology","volume":"13","author":"Datta","year":"2019","journal-title":"Ecancermedicalscience"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-019-0281-x","article-title":"iRECIST: how to do it","volume":"20","author":"Persigehl","year":"2020","journal-title":"Cancer Imag"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00829-y","article-title":"Impact of concomitant cardiovascular medication on survival of metastatic renal cell carcinoma patients treated with sunitinib or pazopanib in the first line","volume":"16","author":"Fiala","year":"2021","journal-title":"Target Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03082","article-title":"Systemic \u03b2-Adrenergic Receptor Activation Augments the ex vivo Expansion and Anti-Tumor Activity of V\u03b39V\u03b42 T-Cells","volume":"10","author":"Baker","year":"2019","journal-title":"Front Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0445","article-title":"Chronic adrenergic stress contributes to metabolic dysfunction and an exhausted phenotype in T cells in the tumor microenvironment","volume":"9","author":"Qiao","year":"2021","journal-title":"Cancer Immunol Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-022-02238-8","article-title":"Dissecting the role of cell signaling versus CD8(+) T cell modulation in propranolol antitumor activity","volume":"100","author":"Li","year":"2022","journal-title":"J Mol Med (Berl)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1894","article-title":"Propranolol suppresses the growth of colorectal cancer through simultaneously activating autologous CD8(+) T cells and inhibiting tumor AKT\/MAPK pathway","volume":"108","author":"Liao","year":"2020","journal-title":"N\/A"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00262-018-2243-8","article-title":"\u03b2-Adrenergic signaling blocks murine CD8(+) T-cell metabolic reprogramming during activation: a mechanism for immunosuppression by adrenergic stress","volume":"68","author":"Qiao","year":"2019","journal-title":"N\/A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0833","article-title":"Blockade of \u03b2-adrenergic receptors improves CD8(+) T-cell priming and cancer vaccine efficacy","volume":"7","author":"Daher","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-20-2381","article-title":"Phase I clinical trial of combination propranolol and pembrolizumab in locally advanced and metastatic melanoma: safety, tolerability, and preliminary evidence of antitumor activity","volume":"27","author":"Gandhi","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1325050","article-title":"Repurposing beta-blockers for combinatory cancer treatment: effects on conventional and immune therapies","volume":"14","author":"Massalee","year":"2023","journal-title":"Front Pharmacol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"New Engl J Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3390\/jcm10071365","article-title":"PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small-cell lung cancer patients with high PD-L1 expression: A network meta-analysis","volume":"10","author":"Majem","year":"2021","journal-title":"J Clin Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.lungcan.2020.04.027","article-title":"ECOG performance status \u22652 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors-A systematic review and meta-analysis of real world data","volume":"145","author":"Dall\u2019Olio","year":"2020","journal-title":"Lung Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1200\/OP.20.01055","article-title":"Impact of performance status on response and survival among patients receiving checkpoint inhibitors for advanced solid tumors","volume":"18","author":"Krishnan","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"B42","doi-asserted-by":"publisher","first-page":"10356","DOI":"10.1038\/s41598-025-95128-1","article-title":"Preoperative ECOG performance status as a predictor of outcomes in upper tract urothelial cancer surgery","volume":"15","author":"Yang","year":"2025","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21785","article-title":"Clinical insights into small cell lung cancer: Tumor heterogeneity, diagnosis, therapy, and future directions","volume":"73","author":"Megyesfalvi","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B44","doi-asserted-by":"publisher","first-page":"17588359251348310","DOI":"10.1177\/17588359251348310","article-title":"Efficacy and safety of first-line PD-1\/PD-L1 inhibitors combined with or without anti-angiogenesis therapy for extensive-stage small-cell lung cancer: a network meta-analysis","volume":"17","author":"Zhou","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1513774","article-title":"Efficacy and safety of immune checkpoint inhibitors for brain metastases of non-small cell lung cancer: a systematic review and network meta-analysis","volume":"15","author":"Liu","year":"2025","journal-title":"Front Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04548-3","article-title":"Extracranial metastasis sites correlate to the incidence risk of brain metastasis in stage IV non-small cell lung cancer: a population-based study","volume":"149","author":"Zhang","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02385-6","article-title":"Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495\/KeyImPaCT trial interim results","volume":"29","author":"Gutierrez","year":"2023","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"116609","DOI":"10.1016\/j.biopha.2024.116609","article-title":"Effects of chronic stress on cancer development and the therapeutic prospects of adrenergic signaling regulation","volume":"175","author":"Zhang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B49","article-title":"Chronic stress promotes tumor immune evasion via the suppression of MHC-I expression and the upregulation of PD-L1","volume":"12","author":"Chen","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.014","article-title":"Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC","volume":"17","author":"Nguyen","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0913","article-title":"Intrinsic immunogenicity of small cell lung carcinoma revealed by its cellular plasticity","volume":"11","author":"Mahadevan","year":"2021","journal-title":"Cancer Discov"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.105973","article-title":"Advancement opportunities and endeavor of innovative targeted therapies for small cell lung cancer","volume":"21","author":"Ouyang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693249\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T05:37:59Z","timestamp":1761025079000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1693249\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":53,"alternative-id":["10.3389\/fimmu.2025.1693249"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1693249","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"article-number":"1693249"}}